Investigational Drug Details
| Drug ID: | D106 |
| Drug Name: | Phenylephrine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00388 |
| DrugBank Description: | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil,[L9413] and induce local vasoconstriction.[A187370] The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s.[A187376] Phenylephrine was granted FDA approval in 1939.[L9413] |
| PubChem ID: | 6041 |
| CasNo: | 59-42-7 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CNC[C@H](O)C1=CC(O)=CC=C1 |
| Structure: |
|
| InChiKey: | SONNWYBIRXJNDC-VIFPVBQESA-N |
| Molecular Weight: | 167.205 |
| DrugBank Targets: | Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor |
| DrugBank MoA: | Phenylephrine is an alpha-1 adrenergic agonist that mediates vasoconstriction[A187370] and mydriasis[L9413] depending on the route and location of administration. Systemic exposure to phenylephrine also leads to agonism of alpha-1 adrenergic receptors, raising systolic and diastolic pressure as well as peripheral vascular resistance.[L9416,L9410] Increased blood pressure stimulates the vagus nerve, causing reflex bradycardia.[L9416,L9410] |
| DrugBank Pharmacology: | Phenylephrine is an alpha-1 adrenergic agonist that raises blood pressure,[L9416,L9410] dilates the pupils,[L9413] and causes local vasoconstriction.[A187370] Ophthalmic formulations of phenylephrine act for 3-8 hours[L9413] while intravenous solutions have an effective half life of 5 minutes and an elimination half life of 2.5 hours.[A187379,L9416] Patients taking ophthalmic formulations of phenylephrine should be counselled about the risk of arrhythmia, hypertension, and rebound miosis.[L9413] Patients taking an intravenous formulation should be counselled regarding the risk of bradycardia, allergic reactions, extravasation causing necrosis or tissue sloughing, and the concomitant use of oxytocic drugs.[L9416,L9410] |
| DrugBank Indication: | Phenylephrine injections are indicated to treat hypotension caused by shock or anesthesia,[L9416, L9410] an ophthalmic formulation is indicated to dilate pupils[L9413] and induce vasoconstriction, an intranasal formulation is used to treat congestion, and a topical formulation is used to treat hemorrhoids.[A187370] Off-label uses include situations that require local blood flow restriction such as the treatment of priapism.[A187370] |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0509 | NCT00745589 | COMPLETED | NO | 2008-07 | 2020-06-18 | Details | |
| L1117 | NCT00032435 | PHASE3 | COMPLETED | NO | 2001-05 | 2010-10-15 | Details |
| L1289 | NCT00534144 | PHASE1 | COMPLETED | NO | 2007-09 | 2011-09-23 | Details |
| L1718 | NCT00077597 | PHASE3 | COMPLETED | NO | 2004-02 | 2016-11-02 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T03 | Angiotensin-converting enzyme | ACE | INHIBITOR | Target is a single protein chain | P12821 | ACE_HUMAN | Details |
| T06 | Sulfonylurea receptor 1 | ABCC8 | Target is a single protein chain | Q09428 | ABCC8_HUMAN | Details | |
| T47 | Sialin | SLC17A5 | Target is a single protein chain | Q9NRA2 | SLC17A5_HUMAN | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|